| Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer F Ye, S Dewanjee, Y Li, NK Jha, ZS Chen, A Kumar, Vishakha, T Behl, ... Molecular cancer 22 (1), 1-40, 2023 | 78 | 2023 |
| Recent progress in histone deacetylase (HDAC) 1 inhibitors as anticancer agent P Patel, SK Wahan, S Vishakha, BD Kurmi, GD Gupta, H Rajak, V Asati Current Cancer Drug Targets 23 (1), 47-70, 2023 | 12 | 2023 |
| Understanding the mechanistic pathways and clinical aspects associated with protein and gene based biomarkers in breast cancer T Behl, A Kumar, Vishakha, A Sehgal, S Singh, N Sharma, S Yadav, ... International Journal of Biological Macromolecules, 126595, 2023 | 4 | 2023 |
| Novel VEGFR-2 Kinase Inhibitors as Anticancer Agents: A Review Focusing on SAR and Molecular Docking Studies (2016-2021). K Kajal, S Mondal, SK Wahan, P Patel Chemistry & Biodiversity, e202200847-e202200847, 2023 | 3 | 2023 |
| A review on silver nanoparticles focusing on applications in biomedical sector A Kumar, DA Vishakha, K Jeet, S Kumar Int. J. Pharmaceut. Sci. Drug Res. 8, 57-63, 2022 | 2 | 2022 |
| FURAN AND BENZOFURAN DERIVATIVES AS PRIVILEGED SCAFFOLDS AS ANTICANCER AGENTS: SAR AND DOCKING STUDIES (2010 to till date) P Patel, R Shakya, V Sharma, V Asati, BD Kurmi, SK Verma, GD Gupta, ... Journal of Molecular Structure, 137098, 2023 | 1 | 2023 |
| An Expedition on Synthetic Methodology of FDA-approved Anticancer Drugs (2018-2021) S Vishakha, N Navneesh, BD Kurmi, G Das Gupta, SK Verma, A Jain, ... Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal …, 2024 | | 2024 |
| Current Trends in the Development of EGFR Inhibitors as Promising Anticancer Agents: Sar and Synthetic Studies from (2010-2020) S Mondal, KD Kajal, SK Wahan, BD Kurmi, P Patel Current Organic Chemistry 27 (1), 2-27, 2023 | | 2023 |
Ankush KumarAssistant professor, Amity Institute of Pharmacy Mohali, PunjabVerified email at cpuh.edu.in
